Xspray Pharma

31.00 SEK

0.00 %

Less than 1K followers

XSPRAY

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

0.00 %

+21.33 %

-34.87 %

-7.99 %

-23.86 %

-29.00 %

-41.18 %

-78.07 %

+2.65 %

Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.

Market cap

1.29B SEK

Turnover

748.24K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

12.2

2026

Annual report '25

6.5

2026

Interim report Q1'26

12.5

2026

General meeting '26

All

Press releases

ShowingAll content types

Press release11/7/2025, 7:52 AM

Redeye: Xspray Pharm (Q3 update) - Two PDUFA dates in 2026

Regulatory press release11/5/2025, 7:00 AM

Interim Report Third Quarter 2025

Press release10/21/2025, 9:45 AM

Xspray Pharma: FDA accepts New Drug Application for XS003 (nilotinib) for the treatment of CML – PDUFA date set for June 18, 2026

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release10/19/2025, 2:43 PM

Redeye: Xspray Pharma - Update after Dasynoc CRL

Regulatory press release10/10/2025, 8:00 AM

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2026

Regulatory press release10/8/2025, 12:40 AM

Xspray Pharma provides update on the FDA process for Dasynoc – observations at contract manufacturer delay approval

Regulatory press release9/30/2025, 1:55 PM

New number of shares and votes in Xspray Pharma after new share issue

Regulatory press release9/11/2025, 6:00 AM

Xspray’s rights issue oversubscribed – over-allotment issue increased and fully utilized

Regulatory press release8/26/2025, 11:10 AM

First day of trading in subscription rights and BTAs moved to August 27

Regulatory press release8/25/2025, 2:55 PM

Xspray publishes disclosure document regarding rights issue

Regulatory press release8/25/2025, 2:45 PM

Xspray receives additional subscription undertakings of SEK 20 million in the ongoing rights issue

Press release8/19/2025, 6:48 AM

Redeye: Xspray Pharma Q2 2025 - Case defining months ahead

Press release8/19/2025, 6:07 AM

Xspray Pharma Submits XS003 to the FDA – The Company’s Second Product Candidate from the HyNap Platform

Regulatory press release8/15/2025, 6:00 AM

Interim Report Second Quarter 2025

Regulatory press release8/15/2025, 5:50 AM

Xspray resolves on a rights issue of approximately SEK 130 million with an over-allotment issue and carries out debt refinancing

Regulatory press release8/12/2025, 6:18 AM

Xspray Pharma signs license agreement with Handa Therapeutics – to receive up to double-digit royalty on Handa’s net proceeds

Regulatory press release7/11/2025, 12:10 PM

XSpray Pharma achieves significant milestone – demonstrating bioequivalence with absorption advantages compared to Tasigna

Regulatory press release6/27/2025, 1:55 PM

Xspray Pharma Passes FDA Pre-Approval Inspection – Key Regulatory Milestone Achieved for Dasynoc

Regulatory press release5/14/2025, 7:10 PM

FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc®

Regulatory press release5/13/2025, 9:03 AM

Bulletin from the annual general meeting of Xspray Pharma AB (publ)

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.